A Phase 2 study of TQB3616 in metastatic breast cancer
Active, Not Recruiting Phase 2 NCT06702618
Study Description
Evaluating the effectiveness and safety of TQB3616 capsules combined with hormonal therapy in advanced breast cancer resistant to CDK4/6 inhibitors
Study Details
- Registry ID:
- NCT06702618
- Conditions:
- Breast Cancer
- Phase:
- Phase 2
- Target Enrollment:
- 33 participants
- Start Date:
- Healthy Volunteers:
- No
Study Locations (15 sites)
-
The Affiliated Hospital of Southwest Medical University
Luzhou, Sichuan, China -
The First Affiliated Hospital of Xi'an Jiao Tong University
Xi'an, Shanxi, China -
Jiangmen Central Hospital
Jiangmen, Guangdong, China -
Hunan Cancer Hospital
Changsha, Hunan, China -
Luohe Central Hospital
Luohe, Henan, China -
The First Affiliated Hospital of Xi'an Jiao Tong University
Xi’an, Shanxi, China -
Xingtai People's Hospital
Xingtai, Hebei, China -
The First Affilliated Hospital of Bengbu Medical University
Bengbu, Anhui, China -
Cancer Hospital of Shandong First Medical University(Shandong Cancer Institute, Shandong Cancer Hospital)
Jinan, Shandong, China -
Jiangsu Provincial People's Hospital
Nanjing, Jiangsu, China -
Tianjin Medical University Cancer Institute & Hospital
Tianjin, Tianjin, China -
Tianjin Medical University Cancer Institute & Hospital
Tianjin, Tianjin Municipality, China -
Hai'an People's Hospital
Nantong, Jiangsu, China -
Liaoning Cancer Hospital
Shenyang, Liaoning, China -
Harbin Medical University Cancer Hostipal
Harbin, Heilongjiang, China
Interested in Participating?
Check your eligibility and learn more about this study on TrialScreen.